197 related articles for article (PubMed ID: 7479390)
1. Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice?
Denis L
Prostate; 1995 Nov; 27(5):233-40. PubMed ID: 7479390
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
[TBL] [Abstract][Full Text] [Related]
4. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Chen XQ; Huang Y; Li X; Zhang P; Huang R; Xia J; Chen N; Wei Q; Zhu YC; Yang YR; Zeng H
Asian J Androl; 2010 Sep; 12(5):718-27. PubMed ID: 20694018
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide dosages used in the treatment of prostate cancer.
Kolvenbag GJ; Nash A
Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
[TBL] [Abstract][Full Text] [Related]
7. Controversies in the management of advanced prostate cancer.
Tyrrell CJ
Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
[TBL] [Abstract][Full Text] [Related]
8. Combined androgen blockade in advanced prostate cancer: looking back to move forward.
Chodak G; Gomella L; Phung de H
Clin Genitourin Cancer; 2007 Sep; 5(6):371-8. PubMed ID: 17956709
[TBL] [Abstract][Full Text] [Related]
9. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
10. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
11. Combined androgen blockade.
Crawford ED
Eur Urol; 1996; 29 Suppl 2():54-61. PubMed ID: 8717465
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness and positioning of MAB therapy for prostate cancer].
Akaza H; Chodak GW; Hirao Y
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
[TBL] [Abstract][Full Text] [Related]
14. [Maximal androgen blockade].
Altwein JE; Mohandessi B
Urologe A; 2000 Jan; 39(1):27-35. PubMed ID: 10663193
[TBL] [Abstract][Full Text] [Related]
15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
16. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
17. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
[TBL] [Abstract][Full Text] [Related]
18. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
Caubet JF; Tosteson TD; Dong EW; Naylon EM; Whiting GW; Ernstoff MS; Ross SD
Urology; 1997 Jan; 49(1):71-8. PubMed ID: 9000189
[TBL] [Abstract][Full Text] [Related]
19. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
20. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group.
Lancet; 1995 Jul; 346(8970):265-9. PubMed ID: 7630245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]